home / stock / esalf / esalf short
Short Information | Eisai Co Ltd (OTCMKTS:ESALF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 5,952 |
Total Actual Volume | 19,706 |
Short Trends | |
---|---|
Cover Days | 8 |
Short Days | 11 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 298 |
Average Short Percentage | 54.71% |
Is there a ESALF Short Squeeze or Breakout about to happen?
See the ESALF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-01-2024 | $0 | $43.25 | $0 | $0 | 23 | 23 | 100% |
06-28-2024 | $43.25 | $43.25 | $43.25 | $43.25 | 189 | 100 | 52.91% |
06-25-2024 | $39.12 | $39.12 | $39.12 | $39.12 | 208 | 200 | 96.15% |
06-24-2024 | $38.15 | $40 | $40 | $38.15 | 497 | 14 | 2.82% |
06-21-2024 | $0 | $38.4 | $0 | $0 | 15 | 6 | 40% |
06-20-2024 | $38.4 | $38.4 | $38.4 | $38.4 | 306 | 301 | 98.37% |
06-14-2024 | $40.1 | $39.56 | $40.1 | $39.26 | 11,435 | 1,400 | 12.24% |
06-12-2024 | $40.62 | $40.62 | $40.62 | $40.62 | 1,092 | 701 | 64.19% |
06-07-2024 | $43 | $42.815 | $43 | $42.805 | 800 | 100 | 12.5% |
06-05-2024 | $44.9 | $44.9 | $44.9 | $44.9 | 1,000 | 1,000 | 100% |
05-28-2024 | $42.4 | $42.4 | $42.4 | $42.4 | 183 | 102 | 55.74% |
05-23-2024 | $42.335 | $42.5 | $42.5 | $42.335 | 355 | 100 | 28.17% |
05-22-2024 | $41.968 | $42 | $42 | $41.968 | 375 | 50 | 13.33% |
05-21-2024 | $42.6 | $42.85 | $42.85 | $42.6 | 1,650 | 1,500 | 90.91% |
05-20-2024 | $0 | $42.84 | $0 | $0 | 70 | 20 | 28.57% |
05-16-2024 | $0 | $42.84 | $0 | $0 | 52 | 41 | 78.85% |
05-14-2024 | $43.655 | $42.84 | $43.655 | $42.54 | 362 | 61 | 16.85% |
05-13-2024 | $44.67 | $44.67 | $44.67 | $44.67 | 167 | 158 | 94.61% |
05-09-2024 | $0 | $42.55 | $0 | $0 | 2 | 2 | 100% |
05-06-2024 | $42.585 | $42.55 | $42.585 | $42.55 | 925 | 73 | 7.89% |
News, Short Squeeze, Breakout and More Instantly...
Eisai Co Ltd Company Name:
ESALF Stock Symbol:
OTCMKTS Market:
Eisai Announces Move to Solo Development and Commercialization of Farletuzumab Ecteribulin (FZEC) Antibody Drug Conjugate (ADC) TOKYO, July 2, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has agreed to end its global strategic collaboration with Bristol Myers Squi...
Eisai: "LEQEMBI" (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China TOKYO and CAMBRIDGE, Mass., June 28, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that the humanized anti-soluble aggregated amyloid-beta (Abeta) monoclo...
Eisai Continues Contract for FY2024 Dementia Examination Project by Tokyo Bunkyo City TOKYO, June 21, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the company has achieved the pre-set performance indicators in FY2023 for the dementia examination project in Bunkyo Cit...